戈胜强,王志亮

• 1:中国动物卫生与流行病学中心

摘要(Abstract)：

病毒样颗粒(Virus-like particles,VLPs)是指由病毒一个或几个结构蛋白自行组装成不含病毒基因组且不能复制、不具有感染能力的病毒样蛋白颗粒。VLPs因能够模拟天然病毒的构象表位而保持了完整病毒颗粒所具有的免疫原性,可诱导机体产生广泛强大的抗病毒免疫反应,阻止病毒侵入机体,在抗病毒性疾病的预防或治疗性疫苗及诊断试剂的研究开发方面具有巨大的应用前景。本文就禽流感病毒样颗粒相关研究进展进行综述,以期为我国禽流感VLPs的研究提供参考。

关键词(KeyWords)： 禽流感;病毒样颗粒;疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 戈胜强,王志亮

DOI: 10.13242/j.cnki.bingduxuebao.002369

参考文献(References)：

• [1]Grgacic E V,Anderson D A,Virus-like particles:pass-port to immune recognition[J].Methods,2006,40(1):60-65.
• [2]Roldao A,Mellado M C,Castilho L R,et al.Virus-likeparticles in vaccine development[J].Expert RevVaccines,2010,9(10):1149-1176.
• [3]Buonaguro L,Devito C,Tornesello M L,et al.DNA-VLP prime-boost intra-nasal immunization induces cellu-lar and humoral anti-HIV-1systemic and mucosal immu-nity with cross-clade neutralizing activity[J].Vaccine,2007,25(32):5968-5977.
• [4]Kang S M and Compans R W,Enhancement of mucosalimmunization with virus-like particles of simian immuno-deficiency virus[J].J Virol,2003,77(6):3615-3623.
• [5]Harro C D,Pang Y Y,Roden R B,et al.Safety andimmunogenicity trial in adult volunteers of a humanpapillomavirus 16 L1virus-like particle vaccine[J].JNatl Cancer Inst,2001,93(4):284-292.
• [6]Bertolotti-Ciarlet A,Ciarlet M,Crawford S E,et al.Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirusexpression vector and administered intramuscularly,intranasally,or orally to mice[J].Vaccine,2003,21(25-26):3885-3900.
• [7]Murata K,Lechmann M,Qiao M,et al.Immunizationwith hepatitis C virus-like particles protects mice fromrecombinant hepatitis C virus-vaccinia infection[J].ProcNatl Acad Sci U S A,2003,100(11):6753-6758.
• [8]Guu T S,Liu Z,Ye Q,et al.Structure of the hepatitisE virus-like particle suggests mechanisms for virusassembly and receptor binding[J].Proc Natl Acad SciUSA,2009,106(31):12992-12997.
• [9]Ye L,Lin J,Sun Y,et al.Ebola virus-like particlesproduced in insect cells exhibit dendritic cell stimulatingactivity and induce neutralizing antibodies[J].Virology,2006,351(2):260-270.
• [10]Yin S,Sun S,Yang S,et al.Self-assembly of virus-like particles of porcine circovirus type 2capsid proteinexpressed fromEscherichia coli[J].Virol J,2010,7:166.
• [11]Spohn G,Jennings G T,Martina B E,et al.A VLP-based vaccine targeting domain III of the West Nilevirus E protein protects from lethal infection in mice[J].Virol J,2010,7:146.
• [12]Landry N,Ward B J,Trepanier S,et al.Preclinicaland clinical development of plant-made virus-like parti-cle vaccine against avian H5N1influenza[J/OL].PLoSOne,2010,5(12):e15559.
• [13]McGinnes L W,Gravel K A,Finberg R W,et al.Assembly and immunological properties of Newcastledisease virus-like particles containing the respiratorysyncytial virus F and G proteins[J].J Virol,2011,85(1):366-377.
• [14]Mortola E,Roy P,Efficient assembly and release ofSARS coronavirus-like particles by a heterologousexpression system[J].FEBS Lett,2004,576(1-2):174-178.
• [15]郭建强,张智清.病毒样颗粒技术的研究进展[J].中国疫苗和免疫,2009,15(02):167-173.
• [16]Buonamassa D T,Greer C E,Capo S,et al.YeastCoexpression of human papillomavirus types 6and 16capsid proteins[J].Virology,2002,293(2):335-344.
• [17]Wu C Y,Yeh Y C,Yang Y C,et al.MammalianExpression of virus-like particles for advanced mimicryof authentic influenza virus[J/OL].PLoS One,2010,5(3):e9784.
• [18]D′Aoust M A,Couture M M,Charland N,et al.Theproduction of hemagglutinin-based virus-like particlesin plants:a rapid,efficient and safe response topandemic influenza[J].Plant Biotechnol J,2010,8(5):607-619.
• [19]Maeda S.Expression of foreign genes in insects usingbaculovirus vectors[J].Annu Rev Entomol,1989,34:351-372.
• [20]Kost T A,Condreay J P,Jarvis D L.Baculovirus asversatile vectors for protein expression in insect andmammalian cells[J].Nat Biotech,2005,23(5):567-575.
• [21]Jarvis D L.Chapter 14Baculovirus-Insect Cell Expres-sion Systems,in Methods in Enzymology[M].RichardR B,Murray P D,Editors.2009,Academic Press.191-222.
• [22]Grace T D.Establishment of four strains of cells frominsect tissues grown in vitro[J].Nature,1962,195:788-789.
• [23]Smith G E,Summers M,Fraser M.Production of hu-man beta interferon in insect cells infected with a bacu-lovirus expression vector[J].Molecular and Cellularbiology,1983,3(12):2156-2165.
• [24]Maeda S,Kawai T,Obinata M,et al.Production ofhumanα-interferon in silkworm using a baculovirusvector[J].Nature,1985,315(6020):592-594.
• [25]Dmochowski L and Grey C E.Electron microscopy oftumors of known and suspected viral etiology[J].TexRep Biol Med,1957,15(3):704-753.
• [26]Dmochowski L.The vital etiology of leukemia[J].Progr Med Virol,1960,3:363-492.
• [27]Dmochowski L.The electron microscopic view of virus-host relationship in neoplasia[J].Prog Exp TumorRes,1963,3:35-147.
• [28]Almeida J D,Hasselback R C,and A W Ham.Virus-like particles in blood of two acute leukemia patients[J].Science,1963,142:1487-1489.
• [29]Bayer M E,Blumberg B S,and Werner B.Particlesassociated with Australia antigen in the sera of patientswith leukaemia,Down′s Syndrome and hepatitis[J].Nature,1968,218(5146):1057-1059.
• [30]Dane D S,Cameron C H,Briggs M.Virus-like parti-cles in serum of patients with Australia-antigen-associated hepatitis[J].Lancet,1970,1(7649):695-698.
• [31]Gomez-Puertas P,Albo C,Perez-Pastrana E,et al.Influenza virus matrix protein is the major driving forcein virus budding[J].J Virol,2000,74(24):11538-11547.
• [32]Latham T and Galarza J M,Formation of wild-type andchimeric influenza virus-like particles following simul-taneous expression of only four structural proteins[J].J Virol,2001,75(13):6154-6165.
• [33]Chen B J,Leser G P,Morita E,et al.Influenza virushemagglutinin and neuraminidase,but not the matrixprotein,are required for assembly and budding of plas-mid-derived virus-like particles[J].J Virol,2007,81(13):7111-7123.
• [34]Quan F S,Huang C,Compans R W,et al.Virus-likeparticle vaccine induces protective immunity againsthomologous and heterologous strains of influenza virus[J].J.Virol.,2007,81(7):3514-3524.
• [35]Chackerian B.Virus-like particles:flexible platformsfor vaccine development[J].Expert Rev Vaccines,2007,6(3):381-390.
• [36]Plummer E M and Manchester M.Viral nanoparticlesand virus-like particles:platforms for contemporaryvaccine design[J].Wiley Interdiscip Rev NanomedNanobiotechnol,2010.
• [37]Lopez-Macias C.Virus-like particle(VLP)-based vac-cines for pandemic influenza:Performance of a VLPvaccine during the 2009influenza pandemic[J].HumVaccines Immunother,2012,8(3).
• [38]Haynes J R.Influenza virus-like particle vaccines[J].Expert Rev Vaccines,2009,8(4):435-445.
• [39]张立霞,于在江,周剑芳,等.流感病毒样颗粒疫苗研究进展[J].病毒学报,2011,27(4):402-408.
• [40]Pearton M,Kang S M,Song J M,et al.Influenzavirus-like particles coated onto microneedles can elicitstimulatory effects on langerhans cells in human skin[J].Vaccine,2010,28(37):6104-6113.
• [41]Kim Y C,Quan F S,Compans R W,et al.Formula-tion of microneedles coated with influenza virus-likeparticle vaccine[J].AAPS PharmSciTech,2010,11(3):1193-1201.
• [42]Quan F S,Kim M C,Lee B J,et al.Influenza M1VLPs containing neuraminidase induce heterosubtypiccross-protection[J].Virology,2012,430(2):127-135.
• [43]Wen Z,Ye L,Gao Y,et al.Immunization by influenzavirus-like particles protects aged mice against lethalinfluenza virus challenge[J].Antiviral Res,2009,84(3):215-224.
• [44]Matassov D,Cupo A,Galarza J M.A novel intranasalvirus-like particle(VLP)vaccine designed to protect a-gainst the pandemic 1918influenza A virus(H1N1)[J].Viral Immunol,2007,20(3):441-452.
• [45]Perrone L A,Ahmad A,Veguilla V,et al.Intranasalvaccination with 1918 Influenza virus-like particlesprotects mice and ferrets from lethal 1918and H5N1influenza virus challenge[J].J Virol,2009,83(11):5726-5734.
• [46]D′Aoust M A,Lavoie P O,Couture M M,et al.Influ-enza virus-like particles produced by transient expres-sion in Nicotiana benthamiana induce a protectiveimmune response against a lethal viral challenge in mice[J].Plant Biotechnol J,2008,6(9):930-940.
• [47]Krammer F,Nakowitsch S,Messner P,et al.Swine-origin pandemic H1N1influenza virus-like particlesproduced in insect cells induce hemagglutinationinhibiting antibodies in BALB/c mice[J].Bio J,2010,5(1):17-23.
• [48]Quan F S,Vunnava A,Compans R W,et al.Virus-like particle vaccine protects against 2009 H1N1pandemic influenza virus in mice[J/OL].PLoS One,2010,5(2):e9161.
• [49]Lopez-Macias C,Ferat-Osorio E,Tenorio-Calvo A,etal.Safety and immunogenicity of a virus-like particlepandemic influenza A(H1N1)2009vaccine in a blin-ded,randomized,placebo-controlled trial of adults inMexico[J].Vaccine,2011,29(44):7826-7834.
• [50]Pushko P,Kort T,Nathan M,et al.RecombinantH1N1 virus-like particle vaccine elicits protectiveimmunity in ferrets against the 2009pandemic H1N1influenza virus[J].Vaccine,2010,28(30):4771-4776.
• [51]LEasterbrook J D,Schwartzman L M,Gao J,et al.Protection against a lethal H5N1influenza challenge byintranasal immunization with virus-like particles contai-ning 2009pandemic H1N1neuraminidase in mice[J].Virology,2012,432(1):39-44.
• [52]Galarza J M,Latham T,Cupo A.Virus-like particle(VLP)vaccine conferred complete protection against alethal influenza virus challenge[J].Viral Immunol,2005,18(1):244-251.
• [53]Galarza J M,Latham T,Cupo A.Virus-like particlevaccine conferred complete protection against a lethalinfluenza virus challenge[J].Viral Immunol,2005,18(2):365-372.
• [54]Bright R A,Carter D M,Daniluk S,et al.Influenzavirus-like particles elicit broader immune responsesthan whole virion inactivated influenza virus or recom-binant hemagglutinin[J].Vaccine,2007,25(19):3871-3878.
• [55]Bright R A,Carter D M,Crevar C J,et al.Cross-clade protective immune responses to influenza viruseswith H5N1HA and NA elicited by an influenza virus-like particle[J/OL].PLoS One,2008,3(1):e1501.
• [56]Kang S M,Yoo D G,Lipatov A S,et al.Induction oflong-term protective immune responses by influenzaH5N1virus-like particles[J/OL].PLoS One,2009,4(3):e4667.
• [57]Song J-M,Kim Y-C,Barlow P G,et al.Improvedprotection against avian influenza H5N1virus by a sin-gle vaccination with virus-like particles in skin usingmicroneedles[J].Anti Res,2010,88(2):244-247.
• [58]Song J M,Kim Y C,Lipatov A S,et al.Microneedledelivery of H5N1influenza virus-like particles to theskin induces long-lasting B-and T-cell responses inmice[J].Clin Vaccine Immunol,2010,17(9):1381-1389.
• [59]Haynes J R,Dokken L,Wiley J A,et al.Influenza-pseudotyped Gag virus-like particle vaccines providebroad protection against highly pathogenic avian influ-enza challenge[J].Vaccine,2009,27(4):530-541.
• [60]Mahmood K,Bright R A,Mytle N,et al.H5N1VLPvaccine induced protection in ferrets against lethal chal-lenge with highly pathogenic H5N1influenza viruses[J].Vaccine,2008,26(42):5393-5399.
• [61]Song J M,Choi C W,Kwon S O,et al.Proteomiccharacterization of influenza H5N1virus-like particlesand their protective immunogenicity[J].J ProteomeRes,2011,10(8):3450-3459.
• [62]Schneider-Ohrum K,Giles B M,Weirback H K,et al.Adjuvants that stimulate TLR3or NLPR3pathwaysenhance the efficiency of influenza virus-like particlevaccines in aged mice[J].Vaccine,2011,29(48):9081-9092.
• [63]Mortimer E,Maclean J M,Mbewana S,et al.Settingup aplatform for plant-based influenza virus vaccineproduction in South Africa[J].BMC Bio,2012,12:14.
• [64]张超林,刘春国,王寿山,等.H5亚型禽流感病毒样颗粒的构建及生物学活性鉴定[J].中国预防兽医学报,2012,34(7):514-517.
• [65]王立强,许龙,周晓巍,等.应用HA、NA、M1和M2蛋白制备H5N1高致病性禽流感病毒样颗粒[J].生物技术通报,2011,22(6):759-763.
• [66]Szecsi J,Boson B,Johnsson P,et al.Induction of neu-tralising antibodies by virus-like particles harbouringsurface proteins from highly pathogenic H5N1 andH7N1influenza viruses[J].Virol J,2006,3:70.
• [67]Wei H J,Chang W,Lin S C,et al.Fabrication ofinfluenza virus-like particles using M2fusion proteinsfor imaging single viruses and designing vaccines[J].Vaccine,2011,29(41):7163-7172.
• [68]Tao P,Luo M,Zhu D,et al.Virus-like particlevaccine comprised of the HA,NA,and M1proteins ofan avian isolated H5N1influenza virus induces protec-tive immunity against homologous and heterologousstrains in mice[J].Viral Immunol,2009,22(4):273-281.
• [69]Ding H,Tsai C,Gutierrez R A,et al.Superiorneutralizing antibody response and protection in micevaccinated with heterologous DNA prime and virus likeparticle boost against HPAI H5N1virus[J/OL].PLoSOne,2011,6(1):e16563.
• [70]Haselhorst T,Garcia J M,Islam T,et al.Avian influ-enza H5-containing virus-like particles(VLPs):host-cell receptor specificity by STD NMR spectroscopy[J].Angew Chem Int Ed Engl,2008,47(10):1910-1912.
• [71]Prel A,Le Gall-Recule G,Jestin V.Achievement ofavian influenza virus-like particles that could be used asa subunit vaccine against low-pathogenic avian influenzastrains in ducks[J].Avian Pathology,2008,37(5):513-520.
• [72]Chang G R L,Lai S Y,Chang P C,et al.Productionof immunogenic one-component avian H7-subtypeinfluenza virus-like particles[J].Process Biochemistry,2011,46(6):1292-1298.
• [73]Pushko P,Tumpey T M,Bu F,et al.Influenza virus-like particles comprised of the HA,NA,and M1proteins of H9N2influenza virus induce protectiveimmune responses in BALB/c mice[J].Vaccine,2005,23(50):5751-5759.
• [74]Pushko P,Tumpey T M,Van Hoeven N,et al.Eval-uation of influenza virus-like particles and Novasomeadjuvant as candidate vaccine for avian influenza[J].Vaccine,2007,25(21):4283-4290.
• [75]Lee D H,Park J K,Lee Y N,et al.H9N2avian influ-enza virus-like particle vaccine provides protectiveimmunity and a strategy for the differentiation of infec-ted from vaccinated animals[J].Vaccine,2011,29(23):4003-4007.
• [76]Giles B M,Bissel S J,Dealmeida D R,et al.Antibodybreadth and protective efficacy are increased by vacci-nation with computationally optimized hemagglutininbut not with polyvalent hemagglutinin-based H5N1virus-like particle vaccines[J].Clin Vaccine Immunol,2012,19(2):128-139.
• [77]Giles B M,Ross T M.A computationally optimizedbroadly reactive antigen(COBRA)based H5N1 VLPvaccine elicits broadly reactive antibodies in mice andferrets[J].Vaccine,2011,29(16):3043-3054.
• [78]Pushko P,Pearce M B,Ahmad A,et al.Influenzavirus-like particle can accommodate multiple subtypesof hemagglutinin and protect from multiple influenzatypes and subtypes[J].Vaccine,2011,29(35):5911-5918.
• [79]Ross T M,Mahmood K,Crevar C J,et al.A trivalentvirus-like particle vaccine elicits protective immuneresponses against seasonal influenza strains in mice andferrets[J/OL].PLoS One,2009,4(6):e6032.
• [80]Quan F S,Steinhauer D,Huang C,et al.A bivalentinfluenza VLP vaccine confers complete inhibition ofvirus replication in lungs[J].Vaccine,2008,26(26):3352-3361.
• [81]Gilbert S C.Virus-like particles as vaccine adjuvants[J].Molecular biotechnology,2001,19(2):169-177.
• [82]Tree J A,Richardson C,Fooks A R,et al.Compari-son of large-scale mammalian cell culture systems withegg culture for the production of influenza virus Avaccine strains[J].Vaccine,2001,19(25-26):3444-3450.
• [83]Capua I,Terregino C,Cattoli G,et al.Development ofa DIVA(differentiating infected from vaccinatedanimals)strategy using a vaccine containing a heterolo-gous neuraminidase for the control of avian influenza[J].Avian Pathology,2003,32(1):47-55.
• [84]Pushko P,Tumpey T M,Bu F,et al.Influenza virus-like particles comprised of the HA,NA and M1proteins of H9N2influenza virus induce protectiveimmune responses in BALB/c mice[J].Vaccine,2005,23(50):5751-5759.
• [85]Driscoll F W.Novavax’s VLP influenza vaccine namedone of top 100 drugs in development today.2011,Available from:http://www.novavax.com/download/releases/4-04-11%20NVAX%20VLP%20Named%20to%20Top%20100_FINAL.pdf.
• [86]NOVAVAX.NOVAVAX Launches Phase II ClinicalTrial of Seasonal Influenza Vaccine.2012;Availablefrom:http://www.novavax.com/download/releases/Novavax%20Launches%20Phase%202%20Seasonal%20Flu%20Study.pdf.
• [87]Driscoll F W.Novavax provides update on influenzaprograms.2012,Available from:http://www.nova-vax.com/download/releases/Novavax%20Provides%20Update%20on%20Influenza%20Programs%20-%20Final2.pdf.
• [88]Product and development of recombinant vaccines.2011;Available from:http://www.neugenesis.com/product-development-recombinant-vaccines.html.
• [89]VLP vaccines.2011,Available from:http://www.redbiotec.ch/vaccines.
• [90]Enveloped and non-envelped virus-like particles.2011,Available from:http://www.ligocyte.com/technolo-gy/virus-like-particles.html.
• [91]Influenza VLP Technology for the Development ofOther Targeted Vaccines.2011;Available from:ht-tp://www.technovax.com/pipeline.html.
• [92]Product pipeline.2011;Available from:http://medi-cago.com/English/Products/product-pipeline/default.aspx.
• [93]Kelly H,Valenciano M.Estimating the effect of influ-enza vaccines[J].Lancet Infect Dis,2011,12(1):5-6.
• [94]Mamelund S E,Riise Bergsaker M A.Vaccine history,gender and influenza vaccination in a household context[J].Vaccine,2011,29(51):9441-9450.
• [95]Rappuoli R,Black S,Lambert P H.Vaccine discoveryand translation of new vaccine technology[J].Lancet,2011,378(9788):360-368.
• [96]Extance A.Cell-based flu vaccines ready for US primetime[J].Nat Rev Drug Discov,2011,10(4):246.
• [97]Liu M A.DNA vaccines:an historical perspective andview to the future[J].Immunol Rev,2011,239(1):62-84.